Cardiovascular
Elucigene kits can be used to assist in the identification of individuals carrying gene mutations responsible for cardiovascular disease. CE marked in vitro diagnostic (IVD) kits are currently available for the detection of gene mutations that lead to thrombophilia and familial hypercholesterolaemia.
Thrombophilia
Venous thrombosis causes an estimated 50,000 deaths per year in the US and has an incidence of 1 per 1000 annually. There are many reported risk factors including a genetic element that can contribute to thrombosis. Cardiovascular disease is a leading cause of death for both men and women in most racial ethnic groups.
Familial Hypercholesterolaemia
Familial Hypercholesterolaemia (FH) is a public health problem throughout the world, there are 10 million people with FH worldwide, the majority of these will suffer from a coronary event before they are 65 years old. FH is caused by mutations in the low-density lipoprotein receptor (LDLR) gene, the apolipoprotein B-100 (Apo B) gene or the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene and has an autosomal dominant pattern of inheritance. A single altered copy (heterozygous) of the gene is sufficient to result in clinical symptoms of the disease, i.e. increased serum cholesterol concentration, tendon xanthomas and premature coronary heart disease.
UK guidelines (link below) recommend that DNA screening is used to identify patients with FH, cascade screening should be applied to identify further family members with FH. individuals with FH can then be treated appropriately to lower their risk to premature coronary disease.
http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuidelineWord.doc
This product is not approved by the FDA and is not available for sale in the US
| Description | Quantity | Catalogue |
|---|---|---|
| Elucigene TRP Elucigene TRP (Thrombosis Risk Panel) provides laboratories with a simple and accurate means of routinely testing for the three most relevant mutations implicated in the risk of developing venous thromboembolism, factor V Leiden (R506Q), Prothrombin 20210A (factor II) and MTHFR (methylenetetrahyrofolate reductase) C677T. Available in both gel based and fluorescent detection (ABI3*** series Genetic Analyzer) formats. |
50 test kit - gel based 50 test kit - gel based without MTHFR 50 test kit - fluorescent based |
TH003B2 TH002B2 - To be discontinued THF03B2 |
|
Elucigene FH20 To be discontinued |
50 test kit |
FH020B2 |
| Cat # | Product | Kit Size | Instructions for Use |
|---|---|---|---|
| TH003B2 | Elucigene TRP (gel based kit) | 50 Tests | EN CS DE EL ES IT PT |
| TH002B2 | Elucigene TRP (gel based kit without MTHFR) | 50 Tests | EN CS DE EL ES IT PT |
| THF03B2 | Elucigene TRP (fluorescent kit) | 50 Tests | EN |
| FH020B2 | Elucigene FH20 | 50 Tests | EN |
| Cat # | Product | Kit Size | MSDS |
|---|---|---|---|
| TH003B2 | Elucigene TRP (gel based kit) | 50 Tests | EN DA DE EL ES FR IT PT SV |
| TH002B2 | Elucigene TRP (gel based kit without MTHFR) | 50 Tests | |
| THF03B2 | Elucigene TRP (fluorescent kit) | 50 Tests | EN |
| FH020B2 | Elucigene FH20 | 50 Tests | EN |
All Elucigene gel based kits for the identification of individuals carrying gene mutations responsible for cardiovascular disease comply with the EC Directive 98/79/EC, carry the CE mark and are manufactured within quality systems accredited to ISO9001:2000 and ISO13485. Full technical support is provided to purchasers of kits to ensure acceptable performance and customer satisfaction.
Elucigene gel based kits are not available for sale in the United States
This product is not approved by the FDA and is not available for sale in the US
For additional availability in other countries please contact your local sales rep or distributor.
Elucigene TRP
English: Click to Download
Deutsch: Click to Download
Francais: Click to Download
Italiano: Click to Download
Elucigene FH20
English: Click to Download